UTHR — United Therapeutics Corporation
$587.50+0.46%
Last close: · regular session
Last 60 sessions
UTHR closed at $587.50 (+0.46%) on Oct 23, 2026. Float: 41.6M shares. Latest SEC filing: 4 on Oct 23, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for UTHR in the TickerWise workspace.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 1,305
- Website: https://www.unither.com
Latest SEC filings for UTHR
Latest UTHR news
- United Therapeutics sets additional $2B stock buyback plan Read article
- LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label Read article
- SGIOY or UTHR: Which Is the Better Value Stock Right Now? Read article
- United Therapeutics (NASDAQ:UTHR) CEO Sells $5,215,025.00 in Stock Read article
- Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback Read article
- UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% Read article
- This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Read article
- United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last? Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.